Redwood City, CA, United States of America

Pieter Timmermans


Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2002-2004

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Pieter Timmermans: Innovator in Combination Therapies

Introduction

Pieter Timmermans is a notable inventor based in Redwood City, CA (US). He has made significant contributions to the field of medicine, particularly in the development of combination therapies for treating proliferative disorders. With a total of 2 patents, his work is paving the way for innovative treatment options.

Latest Patents

Timmermans' latest patents include groundbreaking research on combination therapies using pentafluorobenzenesulfonamides. One of his patents focuses on the use of pentafluorobenzenesulfonamides in conjunction with antineoplastic agents such as gemcitabine or paclitaxel. Another patent explores the combination of pentafluorobenzenesulfonamides with platinum coordination complexes like cisplatin. These innovations are crucial for advancing treatment methodologies in oncology.

Career Highlights

Pieter Timmermans is currently associated with Tularik Limited, where he continues to push the boundaries of medical research. His work has garnered attention for its potential to improve patient outcomes in the treatment of various cancers.

Collaborations

Timmermans collaborates with talented professionals in his field, including Susan Schwendner and Jacqueline Walling. Their combined expertise enhances the research and development efforts at Tularik Limited.

Conclusion

Pieter Timmermans stands out as an influential inventor in the realm of combination therapies, contributing valuable patents that aim to improve cancer treatment. His ongoing work at Tularik Limited and collaborations with esteemed colleagues further solidify his impact in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…